Research
Hormonal
The risk of gastrointestinal adverse events was higher among semaglutide participants than placebo.
Clinicians should monitor for gastrointestinal side effects in patients using semaglutide, although most are manageable.
StrongQualifiesmedium confidence
The risk of gastrointestinal adverse events was higher among semaglutide participants than placebo (RR: 1:47; 95% CI 1.28, 1.68); however, the majority of these events were transient, mild-to-moderate in severity, and did not require treatment discontinuation.
Why this rating
Based on a systematic review and meta-analysis of randomized controlled trials.
Source
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Areesha Moiz et al. · The American Journal of Cardiology · 2024
DOI 10.1016/j.amjcard.2024.04.041
Meta-analysisCited 77×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →